Results 51 to 60 of about 58,659 (191)

Can a new nitroimidazole knockout the unconquered tuberculosis?

Archives of Medicine and Health Sciences, 2020
Pretomanid (PA-824) is the latest drug to get approval from the United States Food and Drug Administration (FDA) for the treatment of tuberculosis (TB).
Dhyuti Gupta, Ajaya Kumar Sahoo, Alok Singh   +2 more
doaj   +1 more source

Malabsorption syndrome as a manifestation of systemic effects in advanced forms of pulmonary tuberculosis [PDF]

, 2014
As of October 2012 84 countries had re¬ported at least 1 case of extensively drug resistant tuberculosis (EDR TB). In November 2012, the WHO epidemiological surveillance stated: all new TB cases in the world are 3,7 % of multi-drug resistant tuberculosis
Ilchyshyn, T.I., Shapovalov, V.P., Todoriko, L.D., Yeremenchuk, I.V.   +3 more
core  

Multidrug-Resistant and Extensively Drug Resistant Tuberculosis in Kashmir, India

Journal of Infection in Developing Countries, 2009
Background: To study the profile of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in tertiary care hospital setting, representing almost the whole affected population in Kashmir valley of India ...
Bikram Singh Datta, Ghulam Hassan, Syed Manzoor Kadri, Waseem Qureshi, Mustadiq Ahmad Kamili, Hardeep Singh, Ahmad Manzoor, Mushtaq Ahmad Wani, Shamas u Din, Natasha Thakur   +9 more
doaj   +1 more source

Microevolution of extensively drug-resistant tuberculosis in Russia.

, 2012
Extensively drug-resistant (XDR) tuberculosis (TB), which is resistant to both first- and second-line antibiotics, is an escalating problem, particularly in the Russian Federation.
Balabanova, Y, Bentley, SD, Brown, T, Casali, N, Drobniewski, F, Harris, SR, Hoffner, SE, Horstmann, RD, Ignatyeva, O, Kontsevaya, I, Nejentsev, S, Nikolayevskyy, V, Parkhill, J   +12 more
core   +1 more source

Drug-Resistant Tuberculosis—Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs [PDF]

, 2017
Tuberculosis was declared a global emergency by the World Health Organization (WHO) in 1993. Following the declaration and the promotion in 1995 of directly observed treatment short course (DOTS), a cost-effective strategy to contain the tuberculosis ...
Abubakar, Ibrahim, Atun, Rifat, Chakaya, Jeremiah, Cox, Helen, Ditiu, Lucica, Ford, Nathan, Grobusch, Martin, Hoelscher, Michael, Lawn, Stephen D., Maeurer, Markus, Marais, Ben, Mchugh, Timothy D., McNerney, Ruth, Memish, Ziad, Migliori, Giovanni-Battista, Mwaba, Peter, O'Grady, Justin, Pletschette, Michel, Ramsay, Andrew, Raviglione, Mario, Schito, Marco, Squire, S. Bertel, Swaminathan, Soumya, Zumla, Alimuddin   +23 more
core  

Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis.

Biomédica: revista del Instituto Nacional de Salud, 2020
Introduction: Multidrug-resistant tuberculosis treatment is effective in 50% of patients due to several factors including antibiotic susceptibility of the microorganism, adverse treatment reactions, social factors, and associated comorbidities ...
Ángela Tobón, Johana Rueda, Diego H. Cáceres, Gloria I. Mejía, Elsa M. Zapata, Fernando Montes, Antonio Ospina, Santiago Fadul, Lizeth Paniagua, Jaime Robledo   +9 more
doaj   +1 more source

Averting epidemics of extensively drug-resistant tuberculosis [PDF]

Proceedings of the National Academy of Sciences, 2009
Extensively drug-resistant tuberculosis (XDR TB) has been detected in most provinces of South Africa, particularly in the KwaZulu-Natal province where several hundred cases have been reported since 2004. We analyzed the transmission dynamics of XDR TB in the region using mathematical models, and observed that nosocomial transmission clusters of XDR TB ...
Sanjay, Basu, Gerald H, Friedland, Jan, Medlock, Jason R, Andrews, N Sarita, Shah, Neel R, Gandhi, Anthony, Moll, Prashini, Moodley, A Willem, Sturm, Alison P, Galvani   +9 more
openaire   +2 more sources

Evidence-based Definition for Extensively Drug-Resistant Tuberculosis

American Journal of Respiratory and Critical Care Medicine, 2021
Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB ...
Roelens, Maroussia, Battista Migliori, Giovanni, Rozanova, Liudmila, Estill, Janne, Campbell, Jonathon, Cegielski, J. Peter, Tiberi, Simon, Palmero, Domingo, Fox, Greg, Guglielmetti, Lorenzo, Sotgiu, Giovanni, Brust, James, Bang, Didi, Lienhardt, Christian, Lange, Christoph, Menzies, Dick, Keiser, Olivia, Raviglione, Mario   +17 more
openaire   +3 more sources

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities [PDF]

, 2012
Tuberculosis is unique among the major infectious diseases in that it lacks accurate rapid point-of-care diagnostic tests. Failure to control the spread of tuberculosis is largely due to our inability to detect and treat all infectious cases of pulmonary
Alexandre Harari, Alimuddin Zumla, Armand, Axelsson-Robertson, Banada, Ben Marais, Betsou, Blakemore, Boehme, Boehme, Cattamanchi, Chow, Cuevas, Cuevas, Cuevas, Cuevas, Diel, Dowdy, Dye, European Centre for Disease Prevention and Control, Ferrara, Giovanni-Batista Migliori, Giuseppe Pantaleo, Green, Harari, Helb, Helen Cox, Hillemann, Hohn, Ibrahim Abubakar, Jeremiah Chakaya, John, Justin O’Grady, Karin Weyer, Keeler, Kemp, Kunnath-Velayudhan, Lawn, Lawn, Lawn, Lawn, Lawn, Lemaire, Lin, Ling, Liu, Long, Lucica Ditui, Lynn Zijenah, Mann, Marais, Marais, Marais, Marais, Marco Schito, Markus Maeurer, Marlowe, Martin P. Grobusch, Martina Casenghi, Matthew Bates, McNerney, Michael Hoelscher, Michel Pletschette, Minion, Moore, Morris, Mwaba, Nathan Ford, Nathanson, National Institute for Health and Clinical Excellence, Nicol, Nicol, Oberhelman, O’Grady, Peter, Peter Mwaba, Peter S. Kim, Rifat Atun, Rose, Ruth McNerney, S. Bertel Squire, Samana Schwank, Sester, Shah, Soumya Swaminathan, Squire, Squire, Steingart, Steingart, Steingart, Steve Lawn, Storla, Temple, Theron, Timothy D. Mchugh, Treatment Action Group, Tully, Vadwai, Van Rie, van Wyk, Wallis, Walzl, Weyer, Wilson, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, Wright, Wright, Zar, Ziad Memish, Zumla, Zumla   +118 more
core   +2 more sources

Utility of para-aminosalicylic acid in drug-resistant tuberculosis: Should it be classified as Group D3 or Group C?

Lung India, 2018
Background: The World Health Organization drug-resistant tuberculosis (DR-TB) 2016 guidelines reclassified para-aminosalicylic acid (PAS) as Group D3 “add-on” drug.
Unnati Desai, Jyotsna M Joshi
doaj   +1 more source